Diligence memo · auto-generated · as of July 3, 2026
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Bluejay Therapeutics, Inc. operates in Pharma, based in SAN MATEO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Bluejay Therapeutics, Inc. has raised $222M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $182M on 2024-05-01.
Most recent recorded round closed around 2024-05-01.
Valuation (modeled)modeled
Provath models Bluejay Therapeutics, Inc. at approximately $2.1B (range $866M–$2.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Series D+ Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 17 months.
Last raise 2.2 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
The last round stepped up 8.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 98% of Pharma peers (310 compared).
Modeled value ranks above 95% of those peers.
Closest niche peers: Mirador Therapeutics, Inc., Autolus Therapeutics plc, Candid Therapeutics, Inc., Halda Therapeutics, LLC, Bright Peak Therapeutics, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.